Randomized Controlled Trial

. 2017 Jul;48(7):1877-1883.

doi: 10.1161/STROKEAHA.116.016274. Epub 2017 Jun 15.

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Thompson G Robinson¹, Xia Wang¹, Hisatomi Arima¹, Philip M Bath¹, Laurent Billot¹, Joseph P Broderick¹, Andrew M Demchuk¹, Geoffery A Donnan¹, Jong S Kim¹, Pablo M Lavados¹, Tsong-Hai Lee¹, Richard I Lindley¹, Sheila C O Martins¹, Veronica V Olavarria¹, Jeyaraj D Pandian¹, Mark W Parsons¹, Octavio M Pontes-Neto¹, Stefano Ricci¹, Shoichiro Sato¹, Vijay K Sharma¹, Thang H Nguyen¹, Ji-Guang Wang¹, Mark Woodward¹, John Chalmers¹, Craig S Anderson²; ENCHANTED Investigators

Affiliations

¹ From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People's Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
² From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People's Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.). canderson@georgeinstitute.org.au.

PMID: 28619989
DOI: 10.1161/STROKEAHA.116.016274

Randomized Controlled Trial

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Thompson G Robinson et al. Stroke. 2017 Jul.

. 2017 Jul;48(7):1877-1883.

doi: 10.1161/STROKEAHA.116.016274. Epub 2017 Jun 15.

Authors

Affiliations

¹ From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People's Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.).
² From the Department of Cardiovascular Sciences, National Institute for Health Research Biomedical Research Unit, University of Leicester, (T.G.R.); George Institute for Global Health, Neurological and Mental Health Division (X.W., H.A., L.B., R.I.L., M.W., J.C., C.S.A.), Faculty of Medicine, University of New South Wales (X.W., H.A., L.B., M.W., J.C., C.S.A.), and Department of Geriatric Medicine, Westmead Clinical School (R.I.L.), University of Sydney, Australia; Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.); Department of Neurology and Rehabilitation Medicine, University of Cincinnati Neuroscience Institute (J.P.B.); Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Canada (A.M.D.); Florey Institute of Neuroscience and Mental Health, University of Melbourne, Victoria, Australia (G.A.D.); Department of Neurology, Asan Medical Center, University of Ulsan, Seoul, Korea (J.S.K.); Department of Neurology and Psychiatry, Clinica Alemana de Santiago, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Chile (P.M.L., V.V.O.); Departamento de Ciencias Neurológicas, Facultad de Medicina, Universidad de Chile, Santiago (P.M.L.); Department of Neurology, Stroke Center, Linkou Chang Gung Memorial Hospital and College of Medicine, Chang Gung University, Taoyuan, Taiwan (T.-H.L.); Stroke Division of Neurology Service, Hospital de Clinicas de Porto Alegre, University of Rio Grande do Sul, Brazil (S.C.O.M.); Department of Neurology, Christian Medical College, Ludhiana, Punjab, India (J.D.P.); Department of Neurology, John Hunter Hospital, University of Newcastle, Australia (M.W.P.); Department of Neurosciences and Behavioral Sciences, Ribeirao Preto Medical School, University of Sao Paulo, Brazil (O.M.P.-N.); Uo Neurologia, USL Umbria 1, Sedi di Citta di Castello e Branca, Italy (S.R.); Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan (S.S.); Yong Loo Lin School of Medicine, National University of Singapore (V.K.S.); Division of Neurology, National University Hospital, Singapore (V.K.S.); Department of Cerebrovascular Disease, 115 People's Hospital, Ho Chi Minh City, Vietnam (T.H.N.); The Shanghai Institute for Hypertension, Rui Jin Hospital, Shanghai Jiaotong University School of Medicine, China (J.-G.W.); Department of Epidemiology, Johns Hopkins University, Baltimore, MD (M.W.); George Institute for Global Health, University of Oxford, United Kingdom (M.W.); Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia (C.S.A.); and The George Institute China, Peking University Health Sciences Center, Beijing (C.S.A.). canderson@georgeinstitute.org.au.

PMID: 28619989
DOI: 10.1161/STROKEAHA.116.016274

Abstract

Background and purpose: Many patients receiving thrombolysis for acute ischemic stroke are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage risk. In a prespecified subgroup analysis, we report comparative effects of different doses of intravenous alteplase according to prior APT use among participants of the international multicenter ENCHANTED study (Enhanced Control of Hypertension and Thrombolysis Stroke Study).

Methods: Among 3285 alteplase-treated patients (mean age, 66.6 years; 38% women) randomly assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) intravenous alteplase within 4.5 hours of symptom onset, 752 (22.9%) reported prior APT use. Primary outcome at 90 days was the combined end point of death or disability (modified Rankin Scale [mRS] scores, 2-6). Other outcomes included mRS scores 3 to 6, ordinal mRS shift, and symptomatic intracerebral hemorrhage by various standard criteria.

Results: There were no significant differences in outcome between patients with and without prior APT after adjustment for baseline characteristics and management factors during the first week; defined by mRS scores 2 to 6 (adjusted odds ratio [OR], 1.01; 95% confidence interval [CI], 0.81-1.26; P=0.953), 3 to 6 (OR, 0.95; 95% CI, 0.75-1.20; P=0.662), or ordinal mRS shift (OR, 1.03; 95% CI, 0.87-1.21; P=0.770). Alteplase-treated patients on prior APT had higher symptomatic intracerebral hemorrhage (OR, 1.82; 95% CI, 1.00-3.30; P=0.051) according to the safe implementation of thrombolysis in stroke-monitoring study definition. Although not significant (P-trend, 0.053), low-dose alteplase tended to have better outcomes than standard-dose alteplase in those on prior APT compared with those not using APT (mRS scores of 2-6; OR, 0.84; 95% CI, 0.62-1.12 versus OR, 1.16; 95% CI, 0.99-1.36).

Conclusions: Low-dose alteplase may improve outcomes in thrombolysis-treated acute ischemic stroke patients on prior APT, but this requires further evaluation in a randomized controlled trial.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01422616.

Keywords: aspirin; brain infarction; hypertension; intracranial hemorrhages; tissue plasminogen activator.

PubMed Disclaimer

Comment in

Another Enchantment From ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study): Are Savings and Safety More Salutary Than Efficacy?
Schellinger PD, Tsivgoulis G. Schellinger PD, et al. Stroke. 2017 Jul;48(7):1720-1722. doi: 10.1161/STROKEAHA.117.017450. Epub 2017 Jun 15. Stroke. 2017. PMID: 28619988 No abstract available.

Cited by

Pre-treatment of Single and Double Antiplatelet and Anticoagulant With Intravenous Thrombolysis for Older Adults With Acute Ischemic Stroke: The TTT-AIS Experience.
Lin SF, Hu HH, Ho BL, Chen CH, Chan L, Lin HJ, Sun Y, Lin YY, Chen PL, Lin SK, Wei CY, Lin YT, Lee JT, Chao AC; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Lin SF, et al. Front Neurol. 2021 Feb 22;12:628077. doi: 10.3389/fneur.2021.628077. eCollection 2021. Front Neurol. 2021. PMID: 33692743 Free PMC article.
Individualized intravenous thrombolytic strategy for acute ischemic stroke with large vessel occlusion on the era of mechanical thrombectomy: cases report.
Xing P, Shen H, Li Z, Yang P, Zhang Y, Liu J. Xing P, et al. Neurol Sci. 2020 Mar;41(3):605-610. doi: 10.1007/s10072-019-04098-6. Epub 2019 Nov 14. Neurol Sci. 2020. PMID: 31728853 Free PMC article.
Coronary Angiography Complicated by Acute Ischaemic Stroke and the Use of Thrombolysis: a Cardiology Perspective and Narrative Review of Current Literature.
Gin J, Yeoh J, Thijs V, Clark D, Ho JK, Horrigan M, Farouque O, Al-Fiadh A. Gin J, et al. Curr Cardiol Rep. 2023 Nov;25(11):1499-1512. doi: 10.1007/s11886-023-01962-y. Epub 2023 Oct 17. Curr Cardiol Rep. 2023. PMID: 37847358 Review.
Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis.
Tan G, Wang H, Chen S, Chen D, Zhu L, Xu D, Zhang Y, Liu L. Tan G, et al. Sci Rep. 2017 Nov 22;7(1):16076. doi: 10.1038/s41598-017-16355-9. Sci Rep. 2017. PMID: 29167555 Free PMC article.
Risk factors of hemorrhagic transformation in acute ischaemic stroke: A systematic review and meta-analysis.
Sun J, Lam C, Christie L, Blair C, Li X, Werdiger F, Yang Q, Bivard A, Lin L, Parsons M. Sun J, et al. Front Neurol. 2023 Feb 20;14:1079205. doi: 10.3389/fneur.2023.1079205. eCollection 2023. Front Neurol. 2023. PMID: 36891475 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Affiliations

Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study)

Authors

Affiliations

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Associated data

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical